Jazz Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JAZZ and other ETFs, options, and stocks.

About JAZZ

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. 

CEO
Renée D. Galá
CEORenée D. Galá
Employees
2,800
Employees2,800
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2005
Founded2005
Employees
2,800
Employees2,800

JAZZ Key Statistics

Market cap
10.38B
Market cap10.38B
Price-Earnings ratio
-26.76
Price-Earnings ratio-26.76
Dividend yield
Dividend yield
Average volume
1.30M
Average volume1.30M
High today
$173.09
High today$173.09
Low today
$162.68
Low today$162.68
Open price
$162.90
Open price$162.90
Volume
1.82M
Volume1.82M
52 Week high
$182.99
52 Week high$182.99
52 Week low
$95.49
52 Week low$95.49

Stock Snapshot

The current Jazz Pharmaceuticals(JAZZ) stock price is $170.88, with a market capitalization of 10.38B. The stock trades at a price-to-earnings (P/E) ratio of -26.76.

As of 2026-01-14, Jazz Pharmaceuticals(JAZZ) stock has fluctuated between $162.68 and $173.09. The current price stands at $170.88, placing the stock +5.0% above today's low and -1.3% off the high.

The Jazz Pharmaceuticals(JAZZ)'s current trading volume is 1.82M, compared to an average daily volume of 1.3M.

In the last year, Jazz Pharmaceuticals(JAZZ) shares hit a 52-week high of $182.99 and a 52-week low of $95.49.

In the last year, Jazz Pharmaceuticals(JAZZ) shares hit a 52-week high of $182.99 and a 52-week low of $95.49.

JAZZ News

Simply Wall St 4d
Is Jazz Pharmaceuticals Still Attractive After 33% Share Price Gain This Year?

Wondering if Jazz Pharmaceuticals is still offering value at around US$161 a share, or if most of the opportunity has already been priced in? The stock is up 3...

Is Jazz Pharmaceuticals Still Attractive After 33% Share Price Gain This Year?
Simply Wall St 5d
Jazz Pharmaceuticals Is Down 5.7% After Strong Ziihera Phase 3 Data - Has The Bull Case Changed?

Jazz Pharmaceuticals recently reported positive Phase 3 HERIZON-GEA-01 results for its HER2-targeted therapy Ziihera (zanidatamab-hrii) in combination with chem...

Jazz Pharmaceuticals Is Down 5.7% After Strong Ziihera Phase 3 Data - Has The Bull Case Changed?
TipRanks 6d
Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer

Jazz Pharmaceuticals (JAZZ) announced the appointment of Thomas Riga as Chief Business Officer, effective January 1. Riga joined Jazz in April 2025 through the...

Analyst ratings

94%

of 18 ratings
Buy
94.4%
Hold
5.6%
Sell
0%

People also own

Based on the portfolios of people who own JAZZ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .